A Phase 2, Multi-Center, Open Label, Randomized Study to Evaluate Efficacy and Safety of Adenoviral p53 (Ad-p53) in Combination With Nivolumab in Patients With Advanced, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; P53 gene therapy - MultiVir (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors MultiVir
- 10 Aug 2018 Nivolumab comparator treatment arm was removed, patient number changed from 40 to 20 and study design also changed.
- 09 Aug 2018 Planned number of patients changed from 40 to 20.
- 09 Aug 2018 Planned End Date changed from 20 May 2020 to 1 Sep 2020.